Tenet Healthcare Earnings Reports

Tenet Healthcare Corporation reported a strong fourth quarter with net income rising to $318 million and adjusted diluted EPS reaching $3.44. Net operating revenue declined to $5.072 billion due to hospital divestitures, but strong ambulatory growth and favorable payer mix partially offset the impact. Adjusted EBITDA improved to $1.048 billion, with a margin of 20.7%.

Tenet Healthcare reported strong third quarter results with net income available to common shareholders of $472 million, or $4.89 per diluted share, and adjusted diluted earnings per share of $2.93. Consolidated Adjusted EBITDA increased 14.5% over the third quarter of 2023, driven by strong ambulatory care performance. The company raised its full year 2024 Adjusted EBITDA outlook by $50 million.

Tenet Healthcare reported strong second-quarter results, exceeding expectations with a net income of $259 million, or $2.64 per diluted share. Adjusted diluted earnings per share were $2.31. The company's consolidated Adjusted EBITDA increased by 12.1% year-over-year to $945 million. The Board of Directors authorized a new $1.5 billion share repurchase program and raised the full-year financial outlook.

Tenet Healthcare reported strong Q4 2023 results, with net income from continuing operations available to common shareholders at $244 million, or $2.30 per diluted share. Adjusted diluted earnings per share from continuing operations was $2.68. Consolidated Adjusted EBITDA increased by 12.8% year-over-year to $1.012 billion.

Tenet Healthcare reported a strong Q3 2023, with net income of $101 million and adjusted EPS of $1.44. The company benefited from same-facility revenue growth and cost controls across its ambulatory care and hospital segments. The FY 2023 Adjusted EBITDA outlook was raised.

Tenet Healthcare reported a net income of $123 million, or $1.15 per diluted share, and an adjusted diluted earnings per share of $1.44 for Q2 2023. The company's ambulatory care segment saw a 16.4% increase in Adjusted EBITDA, and same-facility system-wide surgical cases increased by 6.6%.

Tenet Healthcare reported a net income of $131 million, or $1.16 per diluted share, and an adjusted EPS of $1.44. The company's adjusted EBITDA was $841 million. A $1 billion share repurchase program was also announced.

Tenet Healthcare Corporation reported its Q2 2022 results, showing a net income of $38 million and an Adjusted EBITDA of $843 million. The company reaffirmed its 2022 Adjusted EBITDA outlook. The Ambulatory segment saw revenue growth, while the Hospital segment was impacted by a cybersecurity incident.

Tenet Healthcare reported a net income of $448 million, or $4.12 per diluted share, compared to a net loss of $197 million, or $1.87 per share, in Q3 2020. Adjusted EBITDA reached $855 million, up from $551 million in the prior year. The company raised its full-year 2021 financial guidance, reflecting confidence in continued growth and strong cash flow generation.

Tenet Healthcare reported a strong second quarter in 2021, with net income from continuing operations available to common shareholders of $120 million, or $1.11 per diluted share, compared to $88 million, or $0.83 per diluted share, in Q2 2020. Adjusted EBITDA was $834 million, and adjusted diluted earnings per share from continuing operations were $1.59. The company raised its full-year 2021 financial guidance, citing continued growth, operational improvements, and grant income.

Tenet Healthcare Corporation reported a net income from continuing operations available to common shareholders of $414 million in Q4 2020, compared to a net loss of $3 million in Q4 2019. Adjusted EBITDA for Q4 2020 was $832 million excluding grant income, or $1.278 billion including grant income. The company plans to retire $478 million of debt and anticipates annual interest savings of approximately $33 million.

Tenet Healthcare reported a net loss from continuing operations attributable to common shareholders of $197 million for Q3 2020. However, the company saw growth in net cash from operations and free cash flow. Adjusted EBITDA was $621 million excluding a $70 million reversal of COVID stimulus grant income.

Tenet Healthcare reported net income from continuing operations available to common shareholders of $88 million, or $0.83 per diluted share, in 2Q20. The company's results were significantly impacted by the COVID-19 pandemic, but were partially offset by cost-reduction initiatives and grant income from stimulus relief funds. The financial support of the CARES Act provided an important bridge to minimize the financial crisis the pandemic created, allowing uninterrupted care for our patients and communities.

Tenet Healthcare withdrew its previously announced first quarter and full year financial outlook for 2020 due to the rapidly evolving environment and continued uncertainty related to the COVID-19 pandemic. As of March 31, 2020, Tenet's liquidity position included approximately $350 million of excess cash and cash equivalents and approximately $1.0 billion of borrowing availability under its senior secured revolving credit facility.

Tenet Healthcare reported a net income of $2 million, or $0.02 per diluted share, in 4Q19, compared to a net loss of $5 million, or $0.05 per diluted share, in 4Q18. Adjusted EBITDA was $805 million, up from $684 million in the prior year, and adjusted diluted EPS increased to $0.99 from $0.51 in 4Q18. The company anticipates a spin-off of its Conifer segment by the end of the second quarter of 2021.